GRIFFIN MICHELLE RENEE 4
4 · Adaptive Biotechnologies Corp · Filed Mar 13, 2026
Research Summary
AI-generated summary of this filing
Adaptive Biotechnologies (ADPT) Director Michelle Griffin Sells 15,394 Shares
What Happened
Michelle Griffin, a director of Adaptive Biotechnologies (ADPT), sold 15,394 shares in an open-market transaction on March 11, 2026. The reported weighted-average sale price was $13.91 per share, for a total value of approximately $214,131. This was a sale (not a purchase or award) and is typically considered routine insider selling rather than a direct signal of company prospects.
Key Details
- Transaction date: March 11, 2026; Form 4 filed: March 13, 2026 (filed within the usual 2-business-day window).
- Shares sold: 15,394; weighted-average price: $13.91; total value: ~$214,131.
- Price range reported in footnote: individual trades ranged from $13.84 to $13.96; the reporting person offers to provide a breakdown of the number of shares sold at each price upon request (Footnote F1).
- Shares owned after the transaction: Not specified in the information provided.
- Filing timeliness: Appears timely (filed two days after the transaction); no 10b5-1 plan or tax-withholding notes disclosed in the provided excerpt.
Context
Sales by company directors are common and can be for many personal reasons (liquidity, diversification, tax planning). This single open-market sale should be viewed as factual disclosure rather than a definitive statement about company fundamentals.
Insider Transaction Report
- Sale
Common Stock
[F1]2026-03-11$13.91/sh−15,394$214,131→ 15,625 total
Footnotes (1)
- [F1]The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $13.84 to $13.96, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.